{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:55:10Z","timestamp":1782514510231,"version":"3.54.5"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Russian Scientific Center of Roentgenoradiology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4792-9","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T12:56:51Z","timestamp":1537448211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study"],"prefix":"10.1186","volume":"18","author":[{"given":"Vsevolod I.","family":"Kiselev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levon A.","family":"Ashrafyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina L.","family":"Muyzhnek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeniya V.","family":"Gerfanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina B.","family":"Antonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga I.","family":"Aleshikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazlul H.","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"key":"4792_CR1","first-page":"2013","volume-title":"Cancer incidence and mortality worldwide: IARC Cancer Base No11. Lyon","author":"Globocan","year":"2012","unstructured":"Globocan. Cancer incidence and mortality worldwide: IARC Cancer Base No11. Lyon. France: International Agency for Research on Cancer; 2012. p. 2013."},{"issue":"1","key":"4792_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34\u201343.","journal-title":"N Engl J Med"},{"issue":"10","key":"4792_CR3","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","volume":"14","author":"N Katsumata","year":"2013","unstructured":"Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020\u20136.","journal-title":"Lancet Oncol"},{"issue":"9","key":"4792_CR4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","volume":"27","author":"MA Bookman","year":"2009","unstructured":"Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic Cancer intergroup. J Clin Oncol. 2009;27(9):1419\u201325.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4792_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","volume":"21","author":"MA Bookman","year":"2003","unstructured":"Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group. J Clin Oncol. 2003;21(2):283\u201390.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4792_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ygyno.2012.02.034","volume":"125","author":"IR Noguera","year":"2012","unstructured":"Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012;125(3):640\u20135.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4792_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/GCO.0b013e32834daeed","volume":"24","author":"S Sato","year":"2012","unstructured":"Sato S, Itamochi H. Bevacizumab and ovarian cancer. Curr Opin Obstet Gynecol. 2012;24(1):8\u201313.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"8","key":"4792_CR8","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928\u201336.","journal-title":"Lancet Oncol."},{"issue":"1","key":"4792_CR9","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1186\/s40064-016-2660-0","volume":"5","author":"GH Giornelli","year":"2016","unstructured":"Giornelli GH. Management of relapsed ovarian cancer: a review. Springerplus. 2016;5(1):1197.","journal-title":"Springerplus"},{"issue":"30","key":"4792_CR10","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","volume":"32","author":"A du Bois","year":"2014","unstructured":"du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374\u201382.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4792_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","volume":"27","author":"J Berek","year":"2009","unstructured":"Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009;27(3):418\u201325.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4792_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40259-015-0125-6","volume":"29","author":"JE Frampton","year":"2015","unstructured":"Frampton JE. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer. BioDrugs. 2015;29(2):143\u201350.","journal-title":"BioDrugs"},{"issue":"22","key":"4792_CR13","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"issue":"6024","key":"4792_CR14","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1126\/science.1203543","volume":"331","author":"CL Chaffer","year":"2011","unstructured":"Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559\u201364.","journal-title":"Science"},{"issue":"2","key":"4792_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1582-4934.2007.00211.x","volume":"12","author":"AK Croker","year":"2008","unstructured":"Croker AK, Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med. 2008;12(2):374\u201390.","journal-title":"J Cell Mol Med"},{"issue":"9-10","key":"4792_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.drudis.2010.03.009","volume":"15","author":"\u041c Mimeault","year":"2010","unstructured":"Mimeault \u041c, Batra SK. New promising drug targets in cancer- and metastasis-initiating cells. Drug Discov Today. 2010;15(9-10):354\u201364.","journal-title":"Drug Discov Today"},{"issue":"6","key":"4792_CR17","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/aps.2013.27","volume":"34","author":"K \u0421hen","year":"2013","unstructured":"\u0421hen K, Huang YH, Chen JL. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin. 2013;34(6):732\u201340.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"4792_CR18","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1158\/0008-5472.CAN-05-3153","volume":"66","author":"MS Wicha","year":"2006","unstructured":"Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea \u2013 a paradigm shift. Cancer Res. 2006;66(4):1883\u201390.","journal-title":"Cancer Res"},{"issue":"1","key":"4792_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.canlet.2012.10.023","volume":"338","author":"R Foster","year":"2013","unstructured":"Foster R, Buckanovich RJ, Rueda BR. Ovarian cancer stem cells: working towards the root of stemness. Cancer Lett. 2013;338(1):147\u201357.","journal-title":"Cancer Lett"},{"issue":"1","key":"4792_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jcb.24317","volume":"114","author":"N Ahmed","year":"2013","unstructured":"Ahmed N, Abubaker K, Findlay J, Quinn M. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem. 2013;114(1):21\u201334.","journal-title":"J Cell Biochem"},{"key":"4792_CR21","doi-asserted-by":"publisher","first-page":"620523","DOI":"10.1155\/2011\/620523","volume":"2011","author":"KD Steffensen","year":"2011","unstructured":"Steffensen KD, Alvero AB, Yang Y, Waldstrom M, Hui P, Holmberg JC, et al. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol. 2011;2011:620523.","journal-title":"J Oncol"},{"issue":"1","key":"4792_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13577-010-0002-z","volume":"24","author":"S Hosonuma","year":"2011","unstructured":"Hosonuma S, Kobayashi Y, Kojo S, Wada H, Seino K, Kiguchi K, et al. Clinical significance of side population in ovarian cancer cells. Hum Cell. 2011;24(1):9\u201312.","journal-title":"Hum Cell"},{"issue":"6","key":"4792_CR23","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s11095-010-0146-2","volume":"27","author":"FH Sarkar","year":"2010","unstructured":"Sarkar FH. Current trends in the chemoprevention of cancer. Pharm Res. 2010;27(6):945\u20139.","journal-title":"Pharm Res"},{"key":"4792_CR24","first-page":"307","volume-title":"WHO Classificaihion of tumours of female reproductive organs","author":"RJ Kurman","year":"2014","unstructured":"Kurman RJ, \u0421arcanqiu ML, Herrington CS, Young RH. WHO Classificaihion of tumours of female reproductive organs. Fourth ed. Lyon: IARS; 2014. p. 307.","edition":"Fourth"},{"issue":"1","key":"4792_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejso.2017.11.003","volume":"44","author":"A Llueca","year":"2018","unstructured":"Llueca A, Escrig J, MUAPOS working group (multidisciplinary unit of abdominal pelvic oncology surgery). Prognostic value of peritoneal cancer index in primary advanced ovarian cancer. Eur J Surg Oncol. 2018;44(1):163\u20139.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"4792_CR26","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/CMR.0b013e3283485ff0","volume":"21","author":"MA Hofmann","year":"2011","unstructured":"Hofmann MA, Hauschild A, Mohr P, Garbe C, Weichenthal M, Trefzer U, et al. Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial. Melanoma Res. 2011;21(6):516\u201323.","journal-title":"Melanoma Res"},{"issue":"1","key":"4792_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.022","volume":"143","author":"AA Wright","year":"2016","unstructured":"Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016;143(1):3\u201315.","journal-title":"Gynecol Oncol"},{"key":"4792_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","volume":"59","author":"A Fagotti","year":"2016","unstructured":"Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer. 2016;59:22\u201333.","journal-title":"Eur J Cancer"},{"issue":"1","key":"4792_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1053\/ejso.2002.1380","volume":"29","author":"AG Tentes","year":"2003","unstructured":"Tentes AG, Tripsiannis G, Markakidis S, Karanikiotis C, Tzegas G, Georgiadis G, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. EJSO. 2003;29(1):69\u201373.","journal-title":"EJSO"},{"issue":"6","key":"4792_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/jnci\/djh081","volume":"96","author":"GJ Rustin","year":"2004","unstructured":"Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004;96(6):487\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"4792_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"4792_CR32","unstructured":"Kiselev VI. Anti-estrogenic and anti-proliferative agent to treat and prevent female reproductive system diseases Patent (invention) No 2315594, Russian Federation, priority awarded September 01, 2006 (\u041a\u0438\u0441\u0435\u043b\u0435\u0432 \u0412\u0418. \u0410\u043d\u0442\u0438\u044d\u0441\u0442\u0440\u043e\u0433\u0435\u043d\u043d\u043e\u0435 \u0438 \u0430\u043d\u0442\u0438\u043f\u0440\u043e\u043b\u0438\u0444\u0435\u0440\u0430\u0442\u0438\u0432\u043d\u043e\u0435 \u0441\u0440\u0435\u0434\u0441\u0442\u0432\u043e \u0434\u043b\u044f \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u0438 \u043f\u0440\u043e\u0444\u0438\u043b\u0430\u043a\u0442\u0438\u043a\u0438 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u0439 \u0436\u0435\u043d\u0441\u043a\u043e\u0439 \u0440\u0435\u043f\u0440\u043e\u0434\u0443\u043a\u0442\u0438\u0432\u043d\u043e\u0439 \u0441\u0438\u0441\u0442\u0435\u043c\u044b. \u041f\u0430\u0442\u0435\u043d\u0442 \u043d\u0430 \u0438\u0437\u043e\u0431\u0440\u0435\u0442\u0435\u043d\u0438\u0435 \u0420\u0424 \u21162315594, \u0434\u0430\u0442\u0430 \u043f\u0440\u0438\u043e\u0440\u0438\u0442\u0435\u0442\u0430 01 \u0441\u0435\u043d\u0442\u044f\u0431\u0440\u044f 2006 \u0433\u043e\u0434)."},{"key":"4792_CR33","unstructured":"Kiselev VI, Muyzhnek EL. Pharmaceutical composition to prevent metastasis and increase the sensitivity (sensitization) of tumors to chemotherapy Drugs Patent (invention) No 2328282, Russian Federation, priority awarded April 23, 2007 (\u041a\u0438\u0441\u0435\u043b\u0435\u0432 \u0412\u0418, \u041c\u0443\u0439\u0436\u043d\u0435\u043a \u0415\u041b. \u0424\u0430\u0440\u043c\u0430\u0446\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043a\u043e\u043c\u043f\u043e\u0437\u0438\u0446\u0438\u044f \u0434\u043b\u044f \u043f\u0440\u043e\u0444\u0438\u043b\u0430\u043a\u0442\u0438\u043a\u0438 \u043e\u0431\u0440\u0430\u0437\u043e\u0432\u0430\u043d\u0438\u044f \u043c\u0435\u0442\u0430\u0441\u0442\u0430\u0437\u043e\u0432 \u0438 \u043f\u043e\u0432\u044b\u0448\u0435\u043d\u0438\u044f \u0447\u0443\u0432\u0441\u0442\u0432\u0438\u0442\u0435\u043b\u044c\u043d\u043e\u0441\u0442\u0438 (\u0441\u0435\u043d\u0441\u0438\u0431\u0438\u043b\u0438\u0437\u0430\u0446\u0438\u0438) \u043e\u043f\u0443\u0445\u043e\u043b\u0435\u0439 \u043a \u0445\u0438\u043c\u0438\u043e\u0442\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u043c \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0430\u043c. \u041f\u0430\u0442\u0435\u043d\u0442 \u043d\u0430 \u0438\u0437\u043e\u0431\u0440\u0435\u0442\u0435\u043d\u0438\u0435 \u0420\u0424 \u2116 2328282, \u0434\u0430\u0442\u0430 \u043f\u0440\u0438\u043e\u0440\u0438\u0442\u0435\u0442\u0430 23 \u0430\u043f\u0440\u0435\u043b\u044f 2007 \u0433\u043e\u0434)."},{"issue":"12","key":"4792_CR34","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","volume":"13","author":"P Harter","year":"2006","unstructured":"Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann Surg Oncol. 2006;13(12):1702\u201310.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"4792_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","volume":"21","author":"P Harter","year":"2011","unstructured":"Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21(2):289\u201395.","journal-title":"Int J Gynecol Cancer"},{"key":"4792_CR36","volume-title":"The EORTC QLQ-C30 scoring manual","author":"NW Scott","year":"2001","unstructured":"Scott NW, Fayers PM. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: Uropean organisation for research and treatment of Cancer; 2001.","edition":"3"},{"key":"4792_CR37","unstructured":"Cancer Therapy Evaluation Program: National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.\u00a0 http:\/\/ctep.cancer.gov . Accessed 9 Aug 2006."},{"key":"4792_CR38","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"4792_CR39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc Ser B (Methodological). 1972;34(2):187\u2013220.","journal-title":"J R Stat Soc Ser B (Methodological)"},{"issue":"2","key":"4792_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ygyno.2011.04.008","volume":"122","author":"A Fagotti","year":"2011","unstructured":"Fagotti A, Costantini B, Vizzielli G, Perelli F, Ercoli A, Gallotta V, et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol. 2011;122(2):221\u20135.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"4792_CR41","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","volume":"127","author":"A Fagotti","year":"2012","unstructured":"Fagotti A, Costantini B, Petrillo M, Vizzielli G, Fanfani F, Margariti PA, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol Oncol. 2012;127(3):502\u20135.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4792_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/annonc\/mds282","volume":"24","author":"S. B. Kaye","year":"2012","unstructured":"Kaye SB, Poole CJ, Da\u0144ska-Bidzi\u0144ska A, Gianni L, Del Conte G, Gorbunova V, et al. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Ann Oncol 2013. 24(1):145\u201352.","journal-title":"Annals of Oncology"},{"issue":"26","key":"4792_CR43","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473\u201383.","journal-title":"N Engl J Med"},{"key":"4792_CR44","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.mam.2013.06.002","volume":"39","author":"N Ahmed","year":"2014","unstructured":"Ahmed N, Abubaker K, Findlay JK. Ovarian cancer stem cells: molecular concepts and relevance as therapeutic targets. Mol Asp Med. 2014;39:110\u201325.","journal-title":"Mol Asp Med"},{"key":"4792_CR45","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1100\/tsw.2011.112","volume":"11","author":"I Conic","year":"2012","unstructured":"Conic I, Dimov I, Tasic-Dimov D, Djordjevic B, Stefanovic V. Ovarian epithelial cancer stem cells. Sci World J. 2012;11:1243\u201369.","journal-title":"Sci World J"},{"key":"4792_CR46","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2741\/3693","volume":"16","author":"MD Curley","year":"2011","unstructured":"Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR. Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci (Landmark Ed). 2011;16:368\u201392.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"4","key":"4792_CR47","first-page":"627","volume":"17","author":"B Djordjevic","year":"2012","unstructured":"Djordjevic B, Stojanovic S, Conic I, Jankovic-Velickovic L, Vukomanovic P, Zivadinovic R, et al. Current approach to epithelial ovarian cancer based on the concept of cancer stem cells. J BUON. 2012;17(4):627\u201336.","journal-title":"J BUON"},{"key":"4792_CR48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1476-4598-12-24","volume":"12","author":"K Abubaker","year":"2013","unstructured":"Abubaker K, Latifi A, Luwor R, Nazaretian S, Zhu H, Quinn MA, et al. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol Cancer. 2013;12:24.","journal-title":"Mol Cancer"},{"issue":"10","key":"4792_CR49","doi-asserted-by":"publisher","first-page":"e46858","DOI":"10.1371\/journal.pone.0046858","volume":"7","author":"A Latifi","year":"2012","unstructured":"Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, et al. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One. 2012;7(10):e46858.","journal-title":"PLoS One"},{"issue":"4","key":"4792_CR50","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.3390\/ijms14046624","volume":"14","author":"MJ Kwon","year":"2013","unstructured":"Kwon MJ, Shin YK. Regulation of ovarian cancer stem cells or tumor-initiating cells. Int J Mol Sci. 2013;14(4):6624\u201348.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4792_CR51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.canlet.2008.01.033","volume":"262","author":"JR Wenga","year":"2008","unstructured":"Wenga JR, Tsaic CH, Kulp SK, Che CS. Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett. 2008;262(2):153.","journal-title":"Cancer Lett"},{"issue":"1\u20132","key":"4792_CR52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.mrrev.2011.06.001","volume":"728","author":"S Banerjee","year":"2011","unstructured":"Banerjee S, Kong D, Wang Z, Bao B, Hillman GG, Sarkar FH. Attenuation of multi-targeted proliferation-linked signaling by 3,3\u2032-diindolylmethane (DIM): from bench to clinic. Mutat Res. 2011;728(1\u20132):47\u201366.","journal-title":"Mutat Res"},{"key":"4792_CR53","first-page":"832161","volume":"2014","author":"VL Maruthanila","year":"2014","unstructured":"Maruthanila VL, Poornima J, Mirunalini S. Attenuation of carcinogenesis and the mechanism underlying by the influence of indole-3-carbinol and its metabolite 3,3\u2032-diindolylmethane: a therapeutic marvel. Adv Pharmacol Sci. 2014;2014:832161.","journal-title":"Adv Pharmacol Sci"},{"issue":"2","key":"4792_CR54","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.canlet.2008.04.014","volume":"269","author":"N Khan","year":"2008","unstructured":"Khan N, Mukhtar H. Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett. 2008;269(2):269\u201380.","journal-title":"Cancer Lett"},{"issue":"14","key":"4792_CR55","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2174\/138945012804545650","volume":"13","author":"PK Kandala","year":"2012","unstructured":"Kandala PK, Srivastava SK. DIMming ovarian cancer growth. Curr Drug Targets. 2012;13(14):1869\u201375.","journal-title":"Curr Drug Targets"},{"issue":"3","key":"4792_CR56","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ygyno.2012.04.048","volume":"126","author":"D Trudel","year":"2012","unstructured":"Trudel D, Labb\u00e9 DP, Bairati I, Fradet V, Bazinet L, Tetu B. Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies. Gynecol Oncol. 2012;126(3):491\u20138.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4792_CR57","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s13402-015-0251-7","volume":"39","author":"M Zou","year":"2016","unstructured":"Zou M, Zhang X, Xu C. IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3\u2032-diindolylmethane in ovarian cancer cells. Cell Oncol (Dordr). 2016;39(1):47\u201357.","journal-title":"Cell Oncol (Dordr)"},{"issue":"3","key":"4792_CR58","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1208\/s12248-013-9493-3","volume":"15","author":"TY Wu","year":"2013","unstructured":"Wu TY, Khor TO, Su ZY, Saw CL, Shu L, Cheung KL, et al. Epigenetic modifications of Nrf2 by 3,3\u2032-diindolylmethane in vitro in TRAMP C1 cell line and in vivo TRAMP prostate tumors. The AAPS J. 2013;15(3):864\u201374.","journal-title":"The AAPS J"},{"issue":"4","key":"4792_CR59","first-page":"245","volume":"2","author":"A Haefele","year":"2007","unstructured":"Haefele A, Word B, Yongmei X, Hammons GJ, Lyn-Cook BD. Indole-3-carbinol (I3C) modulates expression of DNA methyltransferases 1, 3a, and 3b in pancreatic cancer cells: effects of gender and a novel (C\u2192T) polymorphism in the promoter region of DNMT 3b. Int J Cancer Prev. 2007;2(4):245\u201355.","journal-title":"Int J Cancer Prev"},{"issue":"22","key":"4792_CR60","first-page":"7563","volume":"63","author":"MZ Fang","year":"2003","unstructured":"Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, et al. Tea polyphenol (\u2212)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003;63(22):7563\u201370.","journal-title":"Cancer Res"},{"issue":"12","key":"4792_CR61","first-page":"4907","volume":"30","author":"BD Lyn-Cook","year":"2010","unstructured":"Lyn-Cook BD, Mohammed SI, Davis C, Word B, Haefele A, Wang H, et al. Gender differences in gemcitabine (Gemzar) efficacy in cancer cells: effect of indole-3-carbinol. Anticancer Res. 2010;30(12):4907\u201313.","journal-title":"Anticancer Res"},{"issue":"2","key":"4792_CR62","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/0008-5472.CAN-09-1924","volume":"70","author":"Y Li","year":"2010","unstructured":"Li Y, Li X, Guo B. Chemopreventive agent 3,3\u2032-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res. 2010;70(2):646\u201354.","journal-title":"Cancer Res"},{"issue":"11","key":"4792_CR63","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/ijc.24988","volume":"126","author":"M Pandey","year":"2010","unstructured":"Pandey M, Shukla S, Gupta S. Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. Int J Cancer. 2010;126(11):2520\u201333.","journal-title":"Int J Cancer"},{"issue":"3","key":"4792_CR64","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.taap.2012.07.007","volume":"263","author":"LM Beaver","year":"2012","unstructured":"Beaver LM, Yu TW, Sokolowski EI, Williams DE, Dashwood RH, Ho E. 3,3\u2032-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. Toxicol Appl Pharmacol. 2012;263(3):345\u201351.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"20","key":"4792_CR65","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2174\/092986710791299966","volume":"17","author":"Y Li","year":"2010","unstructured":"Li Y, Tollefsbol TO. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr Med Chem. 2010;17(20):2141\u201351.","journal-title":"Curr Med Chem"},{"issue":"6","key":"4792_CR66","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s11095-010-0105-y","volume":"27","author":"Y Li","year":"2010","unstructured":"Li Y, Kong D, Wang Z, Sarkar FH. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res. 2010;27(6):1027\u201341.","journal-title":"Pharm Res"},{"key":"4792_CR67","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12915-014-0072-6","volume":"12","author":"AS Tin","year":"2014","unstructured":"Tin AS, Park AH, Sundar SN, Firestone GL. Essential role of the cancer stem\/progenitor cell marker nucleostemin for indole-3-carbinol anti-proliferative responsiveness in human breast cancer cells. BMC Biol. 2014;12:72.","journal-title":"BMC Biol"},{"issue":"1","key":"4792_CR68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bbrc.2012.06.062","volume":"424","author":"A Semov","year":"2012","unstructured":"Semov A, Iourtchenco L, Liu LF, Li S, Yan X, Xiaoxue S, et al. Diindolylmethane (DIM) selectively inhibits cancer stem cells. Biochem Biophys Res Commun. 2012;424(1):45\u201351.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"4792_CR69","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/pros.22901","volume":"75","author":"D Kong","year":"2015","unstructured":"Kong D, Sethi S, Li Y, Chen W, Sakr WA, Heath E, et al. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes. Prostate. 2015;75(2):161\u201374.","journal-title":"Prostate"},{"issue":"10","key":"4792_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047186","volume":"7","author":"D Chen","year":"2012","unstructured":"Chen D, Banerjee S, Cui QC, Kong D, Sarkar FH, Dou QP. Activation of AMP-activated protein kinase by 3,3\u2032-diindolylmethane (DIM) is associated with human prostate cancer cell death in vitro and in vivo. PLoS One. 2012;7(10):e47186.","journal-title":"PLoS One"},{"key":"4792_CR71","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/1472-6882-12-201","volume":"12","author":"\u0421\u041d Lin","year":"2012","unstructured":"Lin \u0421\u041d, Shen YA, Hung PH, Yu YB, Chen YJ. Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines. BMC Complement Altern Med. 2012;12:201.","journal-title":"BMC Complement Altern Med."},{"issue":"9","key":"4792_CR72","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jnutbio.2010.11.001","volume":"22","author":"Y Li","year":"2011","unstructured":"Li Y, Wicha MS, Schwartz SJ, Suna D. Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem. 2011;22(9):799\u2013806.","journal-title":"J Nutr Biochem"},{"issue":"3","key":"4792_CR73","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s12199-011-0239-5","volume":"17","author":"N Nishimura","year":"2012","unstructured":"Nishimura N, Hartomo TB, Pham TV, Lee MJ, Yamamoto T, Morikawa S, et al. Epigallocatechin gallate inhibits sphere formation of neuroblastoma BE(2)-C cells. Environ Health Prev Med. 2012;17(3):246\u201351.","journal-title":"Environ Health Prev Med"},{"issue":"1","key":"4792_CR74","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ijc.26323","volume":"131","author":"SN Tang","year":"2012","unstructured":"Tang SN, Fu J, Nall D, Rodova M, Shankar S, Srivastava RK. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int J Cancer. 2012;131(1):30\u201340.","journal-title":"Int J Cancer"},{"issue":"2","key":"4792_CR75","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3892\/mmr.2012.1198","volume":"7","author":"JN Ho","year":"2013","unstructured":"Ho JN, Jun W, Choue R, Lee J. I3C and ICZ inhibit migration by suppressing the EMT process and FAK expression in breast cancer cells. Mol Med Rep. 2013;7(2):384\u20138.","journal-title":"Mol Med Rep"},{"issue":"3","key":"4792_CR76","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10555-010-9233-4","volume":"29","author":"FH Sarkar","year":"2010","unstructured":"Sarkar FH, Li Y, Wang Z, Kong D. The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. Cancer Metastasis Rev. 2010;29(3):383\u201394.","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"4792_CR77","doi-asserted-by":"publisher","first-page":"e0125402","DOI":"10.1371\/journal.pone.0125402","volume":"10","author":"X Wang","year":"2015","unstructured":"Wang X, Jiang P, Wang P, Yang CS, Wang X, Feng Q. EGCG enhances cisplatin sensitivity by regulating expression of the copper and cisplatin influx transporter CTR1 in ovary cancer. PLoS One. 2015;10(4):e0125402.","journal-title":"PLoS One"},{"issue":"11","key":"4792_CR78","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","volume":"7","author":"DS Tan","year":"2006","unstructured":"Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006;7(11):925\u201334.","journal-title":"Lancet Oncol."},{"issue":"4","key":"4792_CR79","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1023\/A:1023791229361","volume":"22","author":"CP Carmignani","year":"2003","unstructured":"Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev. 2003;22(4):465\u201372.","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"4792_CR80","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","volume":"21","author":"M Friedlander","year":"2011","unstructured":"Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21(4):771\u20135.","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"4792_CR81","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0959-8049(97)00049-X","volume":"33","author":"A Coates","year":"1997","unstructured":"Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer. 1997;33(7):1025\u201330.","journal-title":"Eur J Cancer"},{"issue":"8","key":"4792_CR82","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1200\/JCO.2003.07.128","volume":"21","author":"D Eton","year":"2003","unstructured":"Eton D, Fairclough D, Cella D, Yount SE, Bonomi P, Johnson DH, et al. Early change in patient reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003;21(8):1536\u201343.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4792_CR83","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1023\/A:1026442201191","volume":"6","author":"J Dancey","year":"1997","unstructured":"Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res. 1997;6(2):151\u20138.","journal-title":"Qual Life Res"},{"key":"4792_CR84","unstructured":"Kiselev VI, Smetnik VP, Suturina LV, Selivanov SP, Rudakova EB, Rakhmatullina IR, et al. Indole carbinol (Indinol Forto) is a multitargeted therapy option for cyclic mastodynia. Obstetrics and Gynecology (Russia). 2013; N7:56\u201362 (\u041a\u0438\u0441\u0435\u043b\u0435\u0432 \u0412\u0418, \u0421\u043c\u0435\u0442\u043d\u0438\u043a \u0412\u041f, \u0421\u0443\u0442\u0443\u0440\u0438\u043d\u0430 \u041b\u0412, \u0421\u0435\u043b\u0438\u0432\u0430\u043d\u043e\u0432 \u0421\u041f, \u0420\u0443\u0434\u0430\u043a\u043e\u0432\u0430 \u0415\u0411, \u0420\u0430\u0445\u043c\u0430\u0442\u0443\u043b\u043b\u0438\u043d\u0430 \u0418\u0420 \u0438 \u0434\u0440. \u0418\u043d\u0434\u043e\u043b\u043a\u0430\u0440\u0431\u0438\u043d\u043e\u043b (\u0418\u043d\u0434\u0438\u043d\u043e\u043b \u0424\u043e\u0440\u0442\u043e) \u2013 \u043c\u0435\u0442\u043e\u0434 \u043c\u0443\u043b\u044c\u0442\u0438\u0442\u0430\u0440\u0433\u0435\u0442\u043d\u043e\u0439 \u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u043f\u0440\u0438 \u0446\u0438\u043a\u043b\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u043c\u0430\u0441\u0442\u043e\u0434\u0438\u043d\u0438\u0438. \u0410\u043a\u0443\u0448\u0435\u0440\u0441\u0442\u0432\u043e \u0438 \u0433\u0438\u043d\u0435\u043a\u043e\u043b\u043e\u0433\u0438\u044f. 2013; N7:56\u201362)."},{"key":"4792_CR85","unstructured":"Ashrafyan LA, Kiselev VI, Paltsev MA, Kuznetsov IN, Muizhnek EL, Antonova IB, et al. Method to treat ovarian cancer, variants of its metastasis and recurrence. Patent (invention) No 2582939, Russian Federation, priority awarded June 06, 2015 (\u0410\u0448\u0440\u0430\u0444\u044f\u043d \u041b\u0410, \u041a\u0438\u0441\u0435\u043b\u0435\u0432 \u0412\u0418, \u041f\u0430\u043b\u044c\u0446\u0435\u0432 \u041c\u0410, \u041a\u0443\u0437\u043d\u0435\u0446\u043e\u0432 \u0418\u041d, \u041c\u0443\u0439\u0436\u043d\u0435\u043a \u0415\u041b, \u0410\u043d\u0442\u043e\u043d\u043e\u0432\u0430 \u0418\u0411 \u0438 \u0434\u0440. \u0421\u043f\u043e\u0441\u043e\u0431 \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u0440\u0430\u043a\u0430 \u044f\u0438\u0447\u043d\u0438\u043a\u043e\u0432, \u0432\u0430\u0440\u0438\u0430\u043d\u0442\u043e\u0432 \u0435\u0433\u043e \u043c\u0435\u0442\u0430\u0441\u0442\u0430\u0437\u0438\u0440\u043e\u0432\u0430\u043d\u0438\u044f \u0438 \u0440\u0435\u0446\u0438\u0434\u0438\u0432\u0438\u0440\u043e\u0432\u0430\u043d\u0438\u044f. \u041f\u0430\u0442\u0435\u043d\u0442 \u043d\u0430 \u0438\u0437\u043e\u0431\u0440\u0435\u0442\u0435\u043d\u0438\u0435 \u0420\u0424 \u21162582939, \u0434\u0430\u0442\u0430 \u043f\u0440\u0438\u043e\u0440\u0438\u0442\u0435\u0442\u0430 06 \u0438\u044e\u043d\u044f 2015 \u0433\u043e\u0434\u0430)."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4792-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4792-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4792-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T15:08:03Z","timestamp":1720624083000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4792-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4792"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4792-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]},"assertion":[{"value":"31 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee of the Federal State Budgetary Institution \u201cRussian Scientific Center of Roentgenoradiology\u201d (RSCRR) of the Ministry of Healthcare of the Russian Federation (Moscow), and all study participants submitted written informed consent at the time of enrollment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"904"}}